Introduction
============

Type 2 diabetes mellitus is a chronic metabolic disease that can impose serious damage on human health and the quality of life ([@B39]; [@B12]). Recently, a survey estimated that there will be more than 642 million people suffering from diabetes in nearly all countries by the year 2040 ([@B5]). In a cyclical manner, hyperglycemia also increases diabetes complications by further aggravating the condition, such as hypoglycemia, ketoacidosis, neuropathy, nephropathy, cardiopathy and retinopathy ([@B27]). Currently, the majority of oral hypoglycemic drugs used for the treatment of diabetes have demonstrated side effects and adverse reactions ([@B22]). Therefore, one of the major research areas is discovering and developing alternate drugs with fewer side effects. Medicinal herbs were applied to treat wide range of diseases including diabetic mellitus for a long time before the birth of Western Medicine ([@B2]), and it was well known that their therapeutic function usually accompanied with less side effects compared with the chemical agents such as phenformin and tolbutamide, indicating the use of traditional herbal medicine, which provoked the interest of many researchers worldwide ([@B44]).

Ginseng has been used as a herbal medicine in China for thousands of years and proved to exhibit wide pharmacological properties, such as anti-cancer, anti-diabetes, anti-fatigue, anti-aging, hepatoprotective, and neuroprotective effects ([@B20],[@B21]). The clinical trials also indicated that ginsenoside possessed antihyperglycemic activity and played an important role in the management of diabetic mellitus and its complications ([@B34]; [@B26]; [@B33]). Ginsenoside monomers, such as ginsenoside Rg1, Re, Rb1, Rk1, Rg5, Rg3, Rb2, and Rh2, have wonderful hypoglycemic effect in the diabetic mice models ([@B6]; [@B29]; [@B38]; [@B18]; [@B39]; [@B22]; [@B37]). However, it is difficult to obtain higher quality ginsenoside monomers in terms of purity and solubility, and increased quantity, for patient administration. Therefore, it is also necessary to study the anti-diabetic activity of the ginsenoside mixture, especially protopanaxadiol (PPD) and protopanaxatriol (PPT)-type saponins, which are two important types of the ginsenoside. According to the chemical structural difference of aglycones, ginsenoside can be classified into two main categories: PPD (e.g., Rb1, Rb2, Rb3, Rc, Rd, Rg5, Rk1, and Rg3) and PPT (e.g., Re, Rf, Rk3, Rh4, Rh1, and Rg1) classifications ([@B30]). However, little is known about the anti-diabetic effect of PPD and PPT and its potential underlying mechanisms. Here, the aim of the present study was to explore and compare the effects of PPD and PPT on glucose and lipid metabolism in high-fat diet/streptozocin (STZ)-induced T2DM mice and their underlying mechanisms of action.

Materials and Methods {#s1}
=====================

HPLC Analysis of Ginsenoside PPD and PPT
----------------------------------------

Standard ginsenoside including Rb1, Re, Rg3, Rg5, Rk1, Rk3, Rh1, and Rh4 were purchased from Purification Technology Development Co., Ltd (Chengdu, China). PPD and PPT were synthesized from Rb1 and Re, respectively, and assayed by HPLC (SSI, United States) on a Poroshell 120 EC-C18 column (5 μm, 250 mm × 4.6 mm, OmniGene LLC) at 203 nm. The gradient elution solvent consisted of water (A) and acetonitrile (B). The process of elution was carried out as follows: 0--20 min, 80% A, 20% B; 20--45 min, 80--54% A, 20--46% B; 45--55 min, 54--45% A, 46--55% B; 55--80 min, 45% A, 55% B. The column was eluted at 25°C with a linear gradient of acetonitrile/water from 80:20 to 45:55 (v/v) at a flow rate of 1.5 mL/min, and then the extract were subsequently filtered and lyophilized. The stock solution of PPD/PPT was prepared containing 8% emulsifier EL (Jiangxi Yipusheng Pharmaceutical Co., Ltd, Jiangxi, China), 10% ethyl alcohol (Tianli Chemical Reagent Co., Ltd, Tianjin, China), and 82% saline (Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., Shaanxi, China) for the intraperitoneal injection.

Animals and Diets
-----------------

C57BL/6 mice (6-week-old, 20 ± 2 g male) were supplied by the Experimental Animal Center of the Fourth Military Medical University and housed in a controlled room (constant temperature 25 ± 2°C and humidity 55 ± 5%, 12 h light/dark cycle). The animal experimental design is summarized in **Figure [1](#F1){ref-type="fig"}**. All experiments were performed in compliance with the relevant laws and institutional guidelines, and conducted with the approval of the Northwest University Animal Ethics Committee.

![Animal experimental design. Group 1, NDC group; Group 2, DC group; Group 3, LPPD group; Group 4, HPPD group; Group 5, LPPT group; Group 6, HPPT group.](fphar-08-00506-g001){#F1}

Mice were given the first week to acclimate to their new environment and were given a normal diet. Following the acclimation period, 60 mice were randomly divided into six groups (*n* = 10). Group 1 was given a normal diet (Chow diet, 10% of calories derived from fat, 3.85 kcal/gm, Research Diets, D12450B) with adlibitum access to food and water, and designated as the control group (NDC). Group 2 was given a diabetic diet (60% of calories derived from fat, 5.24 kcal/gm, Research Diets, New Brunswick, NJ, United States, D12492) for 4 weeks, and designated as the diabetic control (DC). Group 3 and Group 4 were given the diabetic diet for 4 weeks and treated with 50 and 150 mg/kg bodyweight of PPD, and designated as the LPPD and HPPD, respectively. Group 5 and Group 6 were given the diabetic diet for 4 weeks and treated with 50 and 150 mg/kg bodyweight of PPT, and designated as the LPPT and HPPT, respectively. The diet, behavior, and appearance of the all mice were recorded daily, and the body weight, food intake, and FBG levels were investigated weekly. On the first day of week 5, mice were administered a dose of 30 mg/kg bodyweight of STZ (Sigma, St Louis, MO, United States) which dissolved in 100 mM citrate buffer via intraperitoneal injection for 4 days. The NDC group was treated with citrate buffer. Exception of the NDC group, FBG levels in other groups more than 11.0 mM after one week STZ injection were confirmed hyperglycemic. From 6 to 10 weeks, mice in groups 3 through 6 were treated with the indicated dose of ginsenoside once a day.

Fasting Blood Glucose, Oral Glucose Tolerance, and Insulin Tolerance Test
-------------------------------------------------------------------------

The FBG was monitored weekly from the initiation of experiment, and measured using a glucometer (ACCU-CHEK, Roche, Germany). The OGTT was conducted in week 9. Following a 16 h fast, mice were administered an oral glucose solution of 1.8 g/kg bodyweight via a gastric tube. Blood samples were collected from the tail vein, and the glucose concentrations were measured at 0 (basal blood glucose levels), 30, 60, 90, and 120 min post-glucose administration. The ITT was given 5 days prior to the completion of the study period. Following a 6 h fast, mice were intraperitoneally injected with 0.8 U/kg bodyweight insulin. Blood samples were collected from the tail vein, and glucose levels were measured at 0, 15, 30, 60, 90, and 120 min post-injection. The AUC for OGTT and ITT was calculated at 0, 30, 60, 90, and 120 min post glucose/insulin administration using the trapezoidal method.

Blood and Tissue Collection
---------------------------

At the completion of the 4 weeks treatment, the mice were fasted for 12 h prior to being sacrificed. Anesthesia was administered via intraperitoneal injection of 50 mg/kg bodyweight pentobarbital sodium. Whole blood samples were collected retro-orbitally, and the serum was isolated by centrifugation at 3500 *g* for 10 min and stored at --80°C. The liver and pancreas were removed, washed, and fixed in 10% formalin solution for histopathological analysis.

Biochemical Parameters
----------------------

Serum insulin levels were measured with rat insulin ELISA kit (Crystal Chem, Downers Grove, IL, United States). The levels of SOD, malondialdehyde (MDA), TC, and TG were determined by a commercial kit (Nanjing Jiancheng Biology Engineering Institute, Nanjing, China). The SOD activity was defined as the amount of enzymatic reaction in 1 mL of serum per min. HDL-C and LDL-C levels were measured using colorimetric enzyme kits (Sigma--Aldrich, MO, United States). The secretion levels of tumor necrosis factor alpha (TNF-α) and IL-6 were measured using ELISA kits (Abcam, Cambridge, United Kingdom). The HOMA-IR was calculated as HOMA-IR = FBG × fasting insulin level/22.5.

Isolation of Total RNA and Real-Time PCR Assay
----------------------------------------------

Total RNA was isolated from the liver using a Trizol reagent (TIANGEN, Life Technologies Corporation 92008, United States). Total RNA (1.0 μg) was reverse transcribed to cDNA using the Thermo Scientific Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., MA, United States). The mRNA expression was quantified by the Light Cycler 480 real-time system (Roche, Switzerland) using the SYBR green Master I kit (Roche, Switzerland). Relative expression level of target mRNA was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA by the 2^-ΔΔCT^ method. The primer sequences used are listed in **Table [1](#T1){ref-type="table"}**.

###### 

The primer sequences were used for qPCR in this study.

  --------------------------------------------------------------------------
           Forward (5' to 3')         Reverse (5' to 3')        Reference
  -------- -------------------------- ------------------------- ------------
  PGC-1α   AAGTGTGGAACTCTCTGGAACTG    GGGTTATCTTGGTTGGCTTTATG   [@B45]

  PEPCK    TGCCTCTCTCCACACCATTGC      TGCCTTCCACGAACTTCCTCAC    [@B45]

  G6Pase   CGACTCGCTATCTCCAAGTGA      GTTGAACCAGTCTCCGACCA      [@B45]

  TNF-α    CCTGTAGCCCACGTCGTAG        GGGAGTAGACAAGGTACAACCC    [@B45]

  IL-6     CAGTTGCCTTCTTGGGACTGA      ACAGGTCTGTTGGGAGTGGT      [@B45]

  MTTP\    AAGCAGAAATTAGAGCTGAAGAC\   CAGTGGCTCTGGAAGACCT\      This work\
  GAPDH    GGAGCGAGATCCCTCCAAAAT      GGCTGTTGTCATACTTCTCATGG   This work
  --------------------------------------------------------------------------

Histological Analysis
---------------------

For H&E staining, liver and pancreas tissues were fixed in 10% formaldehyde and embedded in paraffin wax. The paraffin-embedded liver and pancreas samples were cut into 5 μm sections. The sections were stained with H&E, and subsequently examined using a light microscope for histopathological examination.

Statistical Analysis
--------------------

All data were expressed as the mean ± standard error of mean (SEM). The statistical analysis of the experimental results was analyzed using the SPSS 15.0 (SPSS Inc., Chicago, IL, United States) for windows statistical program. All graphical representations were performed with GraphPad Prism software (Version 5.0, GraphPad Software Inc., San Diego, CA, United States) using one-way analysis of variance (ANOVA) with Tukey's *post hoc* analysis. A *p*-value of \<0.05 was considered statistically significant. *p* \< 0.05, *p* \< 0.01, and *p* \< 0.001 were highlighted with ^∗^, ^∗∗^, and ^∗∗∗^, respectively.

Results
=======

HPLC Analysis and Identification of Ginsenoside PPD and PPT
-----------------------------------------------------------

To identify the main composition present in PPD and PPT, we performed an HPLC analysis (**Figures [2A,B](#F2){ref-type="fig"}**) and the corresponding contents have been summarized in **Table [2](#T2){ref-type="table"}**. The different compounds were quantified by comparing the tR with respect to ginsenoside standards. The results indicated that there are four kinds of ginsenoside existing in PPD and PPT, respectively. The tR of each composition and corresponding contents were as follows: for PPD: 56.66 min, ginsenoside Rg3 (S); 57.40 min, ginsenoside Rg3 (R); 65.29 min, ginsenoside Rk1; and 66.77 min, ginsenoside Rg5. For PPT: 45.23 min, ginsenoside Rh1 (S); 45.80 min, ginsenoside Rh1 (R); 54.50 min, ginsenoside Rk3; and 56.32 min, ginsenoside Rh4.

![HPLC chromatograms of PPD **(A)** and PPT **(B)**.](fphar-08-00506-g002){#F2}

###### 

Composition and content of PPD and PPT analyzed by HPLC*^a^*.

  Compounds   Retention time (tR) (min)   Content (mg/g)
  ----------- --------------------------- ----------------
  Rg3 (S)     56.66                       12.86 ± 0.43
  Rg3 (R)     57.40                       20.20 ± 0.59
  Rk1         65.29                       25.24 ± 0.75
  Rg5         66.77                       41.69 ± 0.92
  Rh1 (S)     45.23                       4.51 ± 0.47
  Rh1 (R)     45.80                       9.85 ± 1.49
  Rk3         54.50                       24.01 ± 4.96
  Rh4         56.53                       61.44 ± 0.74

a

Values are the means ± standard deviations (

n

= 3).

Effects of PPD and PPT on Body Weight and Food Intake
-----------------------------------------------------

To investigate the effects of PPD and PPT on the development of diabetes, we measured the body weight and food intake of high-fat diet-fed and STZ-induced diabetic mice. As shown in **Figure [3A](#F3){ref-type="fig"}**, body weights of mice were significantly increased when a high fat diet was fed, as compared to the NDC group from week 3 to week 4. The body weights of all STZ-injucted groups were declined gradually. After treatment period, the body weights of the HPPD and HPPT treatment groups gradually decreased as compared to the DC group. After treating for 4 weeks, HPPD treatment group showed similar features to NDC group than HPPT group.

![Effects of PPD and PPT on **(A)** body weight and **(B)** food intake in high-fat diet and STZ-induced diabetic mice during the whole feeding period. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 vs. NDC group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. DC group. Different groups were significantly different (*p* \< 0.05).](fphar-08-00506-g003){#F3}

As shown in **Figure [3B](#F3){ref-type="fig"}**, the food intake in high-fat diet groups was dramatically increased as compared to the NDC group during week 1 to week 4. After injecting STZ, food intake was significantly increased in PPD and PPT groups as compared with the NDC group. However, the reduction in food intake of the PPT treatment groups decreased at a slower rate than the PPD groups after 6 and 10 weeks. These data suggest that PPD and PPT can help to alleviate the diabetic symptoms arising appetite reduction.

Effects of PPD and PPT on FBG, OGTT, and ITT
--------------------------------------------

The FBG levels of all the groups are shown in **Figure [4A](#F4){ref-type="fig"}**. Initial FBG levels showed no significant difference between the NDC group and other groups during the first 4 weeks (*p* \> 0.05). After injecting STZ, the FBG levels gradually increased in all DCs when compared to the NDC group (*p* \< 0.001). However, PPD and PPT treatment for 4 weeks obviously reduced the FBG levels in diabetic mice. Moreover, the FBG levels in HPPD group were lower than that in HPPT group after only 2 weeks of treatment (**Figure [4A](#F4){ref-type="fig"}**). After 4 weeks of treatment, the FBG levels both in HPPD and HPPT groups were significantly decreased to 62.7 and 54.1%, respectively, when compared to the DC group. These data showed that PPD and PPT treatments can help to alleviate the diabetic symptom of FBG reduction.

![Effects of PPD and PPT on **(A)** FBG, **(B)** GTT, **(C)** ITT, and **(D,E)** AUC glucose in high-fat diet and STZ-induced diabetic mice. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 vs. NDC group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. DC group. Different groups were significantly different (*p* \< 0.05). ●, NDC group; ■, DC group; ▲, LPPD (PPD 50 mg/kg) group; ▼, HPPD (PPD 150 mg/kg) group; ♢, LPPT (PPT 50 mg/kg); ○, HPPT (PPT 150 mg/kg).](fphar-08-00506-g004){#F4}

The OGTT was performed after an overnight fast (16 h) at week 9 of the experimentation. Following oral administration of glucose, blood glucose levels reached a maximum at 30 min post-glucose gavage in the NDC group, and then gradually decreased (**Figure [4B](#F4){ref-type="fig"}**). While a different trend was observed in the DC group, which is indicative of glucose intolerance. Compared with the DC group, the glucose levels in PPD and PPT groups were significantly reduced in a dose dependent manner. The glucose levels in HPPD group almost reduced to similar levels in the NDC group. The corresponding AUC profile in **Figure [4B](#F4){ref-type="fig"}** has been shown in **Figure [4D](#F4){ref-type="fig"}**. The AUC values of HPPD and HPPT groups were obviously reduced 53.14 and 39.28% as compared with the DC group. These results indicated that PPD and PPT can improve glucose tolerance in diabetic mice.

To verify the effects of PPD and PPT on the ITT levels, we performed an ITT. As shown in **Figure [4C](#F4){ref-type="fig"}**, blood glucose levels in diabetic mice treated with PPD and PPT were significantly lower than in the DC group at 30, 60, 90, and 120 min. Moreover, the optimum dose of HPPD and HPPT groups closely resembled the curve of the NDC group. Concurrently the glucose AUC shown in **Figure [4E](#F4){ref-type="fig"}** revealed a marked reduction with PPD and PPT treatment when compared with the DC group (*p* \< 0.001 and *p* \< 0.01). As speculated, the largest reductions in glucose AUC were HPPD and HPPT treatment groups with reductions by 61.12 and 53.79%, respectively. Above results indicated that treatment with the HPPD and HPPT dramatically improved the ITT in the high-fat diet and STZ-induced diabetic mice, and that HPPD exhibited a better effect on the improvement of ITT than HPPT.

Serum Insulin Levels, HOMA-IR, and C Peptide Levels
---------------------------------------------------

To further evaluate whether HPPD and HPPT can ameliorate diabetic phenotypes, we investigated the levels of insulin, HOMA-IR and C peptide in mice serum (**Figure [5](#F5){ref-type="fig"}**). Compared with the DC group, insulin and C peptide levels were significantly lower in the treatment groups given the optimum dose of HPPD (*p* \< 0.001) (**Figures [5A,C](#F5){ref-type="fig"}**). Furthermore, a significant reduction in HOMA-IR values was observed in all PPD and PPT treatment groups when compared to the DC group, and the HPPD group showed the most robust reduction in HOMA-IR value (*p* \< 0.001) (**Figure [5B](#F5){ref-type="fig"}**). These results indicated that PPD and PPT can ameliorate insulin resistance in diabetic mice.

![PPT and PPD ameliorates insulin level in high-fat diet and STZ-induced diabetic mice. **(A)** Serum insulin content, **(B)** HOMA-IR, **(C)** C peptide level. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, vs. NDC group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. DC group. Different groups were significantly different (*p* \< 0.05).](fphar-08-00506-g005){#F5}

Effect of PPD and PPT on Serum Parameters
-----------------------------------------

Next, we measured serum lipid levels to determine whether treatment with PPD and PPT can improve dyslipidemia, which is closely associated with T2DM. Serum chemistry analysis revealed that high-fat diet and STZ-induced diabetic mice exhibited significant differences in the levels of TC, TG, and LDL-C between the DC group and treatment groups. As presented in **Figures [6A](#F6){ref-type="fig"}--[C](#F6){ref-type="fig"}**, treatment with PPD and PPT significantly reduced the TC, TG, and LDL-C levels as compared to the DC group (*p* \< 0.01). Moreover, the TC, TG and LDL-C levels almost returned to their normal levels after treatment with a high dose of the PPD as composed with the NDC group. However, HDL-C levels were unchanged among the diabetes-induced mice groups (**Figure [6D](#F6){ref-type="fig"}**).

![PPD and PPT ameliorates lipid disorders in high-fat diet and STZ-induced diabetic mice. **(A)** TC, **(B)** TG, **(C)** LDL-C, **(D)** HDL-C, **(E)** TNF-α, **(F)** IL-6, **(G)** SOD, **(H)** MDA. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 vs. NDC group, ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. DC group. Different groups were significantly different (*p* \< 0.05).](fphar-08-00506-g006){#F6}

We also analyzed the secretion of inflammatory cytokines like TNF-α and IL-6 because abnormalities in inflammation are another characteristic of T2DM. Compared with the DC group, the serum levels of TNF-α and IL-6 were markedly decreased by PPD and PPT in a dose dependent manner. In the same dosage, the inhibited effects of the PPD on TNF-α and IL-6 were more than PPT (**Figures [6E,F](#F6){ref-type="fig"}**). These results indicated that PPD and PPT could ameliorate the inflammatory state in diabetic mice, and that PPD is better than PPT in improving inflammation.

The activities of SOD and MDA play a vital role in maintaining the balance of oxidation and anti-oxidation in the body, particularly for diabetes. Hence, we investigated the activity of SOD and MDA in the T2DM mice treated by PPD and PPT. Compared with the NDC group, the SOD activity in high-fat diet and STZ-induced mice was significantly reduced, but the activity of MDA was opposite. Treatment with PPD or PPT was observed to increase the SOD activity, and decrease the MDA activity in a dose dependent manner (**Figures [6G,H](#F6){ref-type="fig"}**). These results showed that PPD and PPT can improve the level of membrane lipid peroxidation in the T2DM mice.

Histology of the Liver and Pancreas
-----------------------------------

The effect of PPD and PPT on the hepatic histological changes was determined using H&E staining (**Figure [7A](#F7){ref-type="fig"}**). The hepatocytes showed regular distribution or nest the bands of arrangement. A typical architecture of the hepatic lobules was observed in the NDC group. In contrast, the DC group showed degenerative changes in the hepatocytes. After PPD and PPT treatment, the degeneration of the hepatocytes was significantly alleviated, and its architecture gradually returned to the normal state, especially in HPPT group. We also investigated whether there was an effect of PPD and PPT treatment on the islet cells of the pancreas. The results showed that a marked difference was observed in the number of islets cells between the DC group and the treatment groups (**Figure [7B](#F7){ref-type="fig"}**). Treatment with HPPD and HPPT obviously increased the number of pancreatic β-cells as compared with the DC group. We also found that the extent of cellular repair was greater with HPPD treatment as compared with HPPT treatment. Administration of HPPD and HPPT showed partial restoration of the impaired pancreatic cells due to pancreatic cell size was larger and islet cell number was increased.

![Effects of PPD and PPT on hepatic and panscrea in high-fat diet and STZ-induced diabetic mice. H&E staining of the hepatic (final magnification 400×) **(A)** and pancreas (final magnification 200×) **(B)**.](fphar-08-00506-g007){#F7}

Effects of PPD and PPT on Hepatic Glucose Metabolism, Inflammation, and Lipid Metabolism
----------------------------------------------------------------------------------------

To further explore the effects of PPD and PPT on diabetes, we analyzed the relative expression of key genes involved in gluconeogenesis and glycolysis. Gene expression levels of PGC-1α, PEPCK, and G6Pase were down regulated (*p* \< 0.001) in the liver of mice in the HPPD and HPPT groups as compared to those in the DC group (**Figure [8A](#F8){ref-type="fig"}**). These results indicated that treatment with HPPD and HPPT showed a beneficial effect on abnormal hepatic glucose metabolism. We also measured the relative expression of two key markers of inflammation: TNF-α and IL-6. As shown in **Figure [8B](#F8){ref-type="fig"}**, a significant decrease was observed in expression of TNF-α and IL-6 in the liver of the HPPD and HPPT groups as compared with the DC group (*p* \< 0.001). These data supported the notion that PPD and PPT treatment can ameliorate the T2DM-induced inflammatory responses. Furthermore, to understand whether PPD and PPT can regulate lipid metabolism, we detected the gene expression of microsomal triglyceride transfer protein (MTTP), which plays an important role in lipid transport, metabolism and secretion of lipoproteins. The relative expression of MTTP was dramatically reduced in the liver of the DC group as compared with the NDC group. However, PPD and PPT treatment significantly augmented the expression levels of MTTP in the liver of T2DM mice in a dose dependent manner (**Figure [8C](#F8){ref-type="fig"}**). Such results indicated that PPD and PPT may help to ameliorate the augmented T2DM-induced lipid metabolic disorder.

![Effects of PPD and PPT in liver of relative mRNA expressions of **(A)** PGC-1α, PEPCK, G6Pase, **(B)** TNF-α, IL-6, **(C)** MTTP in high-fat and STZ-induced diabetic mice; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 vs. NDC group, ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. DC group. Different groups were significantly different (*p* \< 0.05).](fphar-08-00506-g008){#F8}

Discussion
==========

Ginsenosides, as potential active ingredients of ginseng, have been studied for their hypoglycaemic activity for many years ([@B10]). Some of the ginsenosides such as Rb1, Rb2, Rc, Re, Rg3, Rh2, Rg5, and compound K have been reported to possess anti-diabetic activities ([@B7]; [@B19]; [@B42]; [@B23], [@B22]; [@B41]). However, there is no report on comparison of anti-diabetic effects between PPD and PPT. Hence, it would be interesting to compare anti-diabetic activities of PPD and PPT. In the present study, the anti-diabetic effects of PPD and PPT were investigated using the obese-diabetic rat model by high-fat diet and low-dose STZ injection which would closely mimic the natural history of the disease events as well as the metabolic characteristics of human T2DM ([@B35]).

The present work is the first to comprehensively study the effects of PPD and PPT on T2DM mice induced by high-fat diet and low-dose STZ. T2DM leads to disorders related toglucose and fatty acids metabolism. The characteristic symptoms of T2DM include an increased desire for food associated with body weight loss and hyperglycemia ([@B35]; [@B3]). In diabetic mice, the body weight decreased due to the decrease in glucose metabolism and increase in fat metabolism ([@B31]). According to our results, treatment with PPD and PPT ameliorated these parameters which were able to improve body weight and food intake at the end of the intervention period, indicating a regulatory effect on these metabolic disorders. Hyperglycemia, the most important feature of diabetes mellitus, is in itself very dangerous for diabetic patients. It impairs the prooxidant/antioxidant balance, reducing antioxidant levels and increasing free radicals ([@B1]), which can damage the pancreatic β-cells and induce insulin resistance. Epidemiological studies ([@B14]) and clinical trials ([@B36]) also strongly support the notion that hyperglycemia is the principal cause of complications. Our study showed that PPD exhibited significant reduction of FBG on week 2 and to reach the values of FBG showed in the NDC group. PPT also exhibited a decreasing trend after the 4 weeks treatment, although weaker than PPD. Our results demonstrated that PPD exhibit a hypoglycemic effect *in vivo*, which is in consistence with the results of previous studies with db/db mice ([@B17]). Our results also clearly demonstrated that PPD and PPT could improve the glucose homeostasis. The OGTT levels decreased significantly after 4 weeks of treatment. More importantly, the ITT results indicated that treatment of PPD significant improved the insulin resistance. In addition, diabetes leads to a progressive accumulation of lipid metabolites. The levels of TG, TC, LDL-C, and HDL-C are considered as important biomarkers of hyperlipidemia ([@B3]). Our results confirmed that the PPD showed a strong hypolipidemic effect as well as a hypoglycemic effect through the reduction of TG, TC, LDL-C but showed no effect on HDL-C in diabetic mice. However, these findings indicated that PPD work better than PPT. To our best knowledge, this is the first report demonstrating that PPD is better than PPT in treating T2DM. One possible reason is that PPD contains rich ginsenoside Rg5 (41.69 ± 0.92 mg/g, **Table [2](#T2){ref-type="table"}**), which exhibits good anti-diabetic effect as demonstrated by our results (data not show) and other groups data ([@B41]). In addition, oxidative stress is generally accepted as a likely causative factor in the development of insulin resistance and complications of diabetes ([@B9]). Previous studies have shown that ginsenoside Re and fermented red ginseng extracts significantly enhance SOD activity and reduce MDA level in diabetic mice ([@B13]; [@B24]). Oxidative stress in diabetes is also associated with a reduction in antioxidant capacity, which can compound the deleterious effects of free radicals. The antioxidant enzymes such as SOD and MDA play a major role in scavenging toxic free radicals. The activity changes of these enzymes can reflect the degree of diabetic effect ([@B32]). Indeed, our data showed a strong correlation between the PPD and the antioxidant activity through the improvement of the SOD and reduction of MDA activities, which are considered as markers of the antioxidant system in the organism. The high antioxidant capacity of PPD may be due to its ability of scavenging toxic free radicals.

A major cause of fasting hyperglycemia in T2DM is the increase of hepatic glucose production ([@B8]). Inhibition of hepatic glucose production contributes to glycemic control in the diabetic patients by insulin sensitizers ([@B16]). Previous studies showed that inhibition of hepatic glucose production is one of the underlying mechanisms action of metformin ([@B11]). Our data suggest that PPD inhibits glucose production in liver. The inhibition is related to suppress the gene expressions of PGC-1α, PECPK, and G6Pase in the liver. This might be attributed to the alteration of hepatic insulin resistance ([@B43]). Downregulation of PGC-1α, PECPK, and G6Pase in the liver improves hepatic insulin sensitivity and inhibition of hepatic glucose production in db/db mice ([@B15]). Thus, modulation of PGC-1α, PECPK, and G6Pase activities in the liver may play important roles in systemic glucose homeostasis and hepatic insulin resistance. Hepatic inflammation is an underlying cause of the pathogenesis of chronic diseases such as insulin resistance associated with T2DM ([@B46]). Liver inflammation leads to the secretion of pro-inflammatory cytokines and chemokines, which leads to subsequent progression of these chronic diseases ([@B4]). In the present study, the degree of inflammation activation was evaluated by the expression of inflammatory mediators including TNF-α and IL-6. We found that treatment with PPD significantly down-regulated gene expressional levels of these inflammatory parameters, suggesting that the high-fat diet and STZ-induced hepatic inflammatory reactions were suppressed by PPD. To evaluate the role of the liver in the uptake and release of lipid by lipoprotein, we evaluated the gene expression of MTTP. MTTP is essential for the synthesis of VLDL in the liver. By the increased expression of MTTP, the development of steatosis can be slowed down ([@B40]). In this study, MTTP was significantly reduced in the DC group as compared to the NDC group. Furthermore, the trends of treatment groups were same as that of the NDC group. Based on these observations, it is conceivable that the higher expression of MTTP have played a synergistic role in decreasing hepatic TG levels in HPPD and HPPT.

In most human studies, improved FBG has been known to be more important in T2DM. Ginsenoside is effective in the preventing hyperglycemia in diabetes patients ([@B25]). Previous study revealed that high-dose (8.68 mg/day) or long-term (4 weeks) ginsenoside treatment ameliorated diabetic conditions ([@B28]). In this study, we investigated the impact of the ginsenoside extracts, PPD and PPT, on high-fat diet and STZ-induced T2DM mice. Treatment with a relatively lower dose (3.75 mg/day) or a shorter period of time (2 weeks), can significantly improve FBG, insulin resistance, and the dyslipidemia.

Conclusion
==========

Our data suggest that PPD and PPT could be developed as potentially natural anti-diabetic compounds for preventing and treating the obesity-linked diabetes. After PPD and PPT treatment with the dose range between 50 and 150 mg/kg, the diabetic parameters were shown to improve in a dose-dependent manner. Unfortunately, this study was limited by a lack of sufficient mechanistic studies, a small number of subjects, and the evaluation of only short-term effects of PPD and PPT supplementation. Despite these limitations, this study is important because of the novel exploration of specific subsets of ginsenoside. Our results are promising for treating diabetes and generally consistent with other studies. Further studies with a larger number of subjects and longer duration would further broaden our knowledge regarding the same.
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